Osoba D
Communities Oncology Program, British Columbia Cancer Agency, Vancouver, Canada.
Pharmacoeconomics. 1995 Apr;7(4):308-19. doi: 10.2165/00019053-199507040-00005.
Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multiple domains; (ii) the importance of self-rating; (iii) the reports of counter-intuitive results; (iv) the ability to quantify the effects of symptoms on health-related quality of life; and (v) the prognostic value of health-related quality of life measurement for survival. Many challenges lie ahead. Among these are the difficulties encountered by medical clinicians in choosing appropriate instruments to measure health-related quality of life, the dilemma of choosing between aggregate scores and domain scores, questions surrounding the significance of results, and whether measurement of health-related quality of life is now at a point where it can be used in routine practice outside of the clinical trials setting. Although further research is required in all of these and other areas, the future for health-related quality-of-life measurement in oncology is promising.
对癌症患者健康相关生活质量的测量主要集中在开发可靠且有效的工具（问卷）以及三期临床试验中化疗的效果上。从这项研究中得出了几个重要的经验教训，例如：（i）需要测量多个领域；（ii）自我评估的重要性；（iii）反直觉结果的报告；（iv）量化症状对健康相关生活质量影响的能力；以及（v）健康相关生活质量测量对生存的预后价值。未来仍有许多挑战。其中包括医学临床医生在选择合适的工具来测量健康相关生活质量时遇到的困难、在综合评分和领域评分之间进行选择的困境、围绕结果意义的问题，以及健康相关生活质量的测量目前是否已达到可在临床试验环境之外的常规实践中使用的阶段。尽管在所有这些以及其他领域都需要进一步研究，但肿瘤学中健康相关生活质量测量的未来前景广阔。
